XML 27 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash provided by (used for) operating activities    
Net income (loss) $ 493 $ 314
Depreciation and amortization 304 285
Deferred and prepaid income taxes 31 19
Stock-based compensation expense 63 55
Net loss (gain) on investments and notes receivable 2 31
Contingent consideration net expense (benefit) 17 12
Other, net (4) (2)
Trade accounts receivable (114) (86)
Inventories (124) (185)
Other assets (55) (41)
Accounts payable, accrued expenses and other liabilities (450) (211)
Cash provided by (used for) operating activities 164 190 Close
Investing activities:    
Purchases of property, plant and equipment and internal use software (179) (111)
Proceeds from sale of property, plant and equipment 1 3
Payments for acquisitions of businesses, net of cash acquired (47) (375)
Payments for investments and acquisitions of certain technologies, net of investment proceeds (66) (10)
Proceeds from royalty rights 7 9
Cash provided by (used for) investing activities (285) (484) Close
Financing activities:    
Payment of contingent consideration previously established in purchase accounting (34) (34)
Payments for royalty rights (15) (34)
Payments for finance leases (25) 0
Payments on short-term borrowings (504) 0
Proceeds from long-term borrowings, net of debt issuance costs 2,145 0
Cash dividends paid on preferred stock 0 (14)
Cash used to net share settle employee equity awards (78) (50)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 80 63
Cash provided by (used for) financing activities 1,569 (69) Close
Effect of foreign exchange rates on cash (7) 0 Close
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 1,441 (363) Close
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 1,055 1,126
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 2,496 763
Supplemental Information    
Stock-based compensation expense 63 55
Non-cash impact of transferred royalty rights (7) (9)
Cash and cash equivalents 2,329 570
Restricted cash and restricted cash equivalents included in Other current assets 93 135
Restricted cash equivalents included in Other long-term assets 74 57
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 2,496 $ 763